Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00231582
Other study ID # P031101
Secondary ID
Status Completed
Phase Phase 2
First received October 3, 2005
Last updated February 24, 2011
Start date September 2004
Est. completion date January 2010

Study information

Verified date March 2007
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

High-dose chemotherapy (HD-CT) is able to circumvent platinum-resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach.

Patients with relapsed (but not absolutely refractory to Cisplatinum-based chemotherapy) poor-prognosis GCTs are scheduled to receive 2 cycles combining epirubicin and paclitaxel followed by 3 consecutive HD-CT supported by stem cell transplantation. One course will combine Taxol, 360 mg/m² + thiotepa, 720 mg/m², followed by two ICE regimens (Ifosfamide, 12 g/m², carboplatin, AUC 20, etoposide, 1500 mg/m²).

This phase II study is designed as a Gehan method. The main objective of the study is the complete response rate. With this aim in view, it is planned to enroll in its first step 14 patients to insure that if no complete response (CR) is noticed, study would be stopped for inefficacy (i.e., a CR rate lower than 20%). If one or more CR are noticed, protocol specified that up to 45 patients will be included in order to reduce the confidence interval (CI) of the CR rate. Secondary objectives are the overall response rate (RR), the overall survival (OS) and the progression-free survival (PFS) rates, toxicity and toxic death rate. The statistical analysis is done in terms of intent-to-treat.


Description:

The treatment is designed for relapsed poor prognosis patients with testicular or extra-gonadal GCTs previously treated with cisplatin-containing regimens.

Poor prognosis patients are defined as either relapsed/refractory patients more than one month after cisplatin administration, whether in the course of first-line CT or in that of salvage treatment, or patients who showed evidence of progression after at least 2 lines of cisplatin-containing CT (i.e., BEP and VeIP).

Eligibility requirements includes the following criteria: age >18 years and < 65, performance status < 3, histologically or biologically documented GCTs, testicular, abdominal or mediastinal tumors, measurable or evaluable disease, life expectancy > 3 months, normal cardiac, liver, and renal function tests, absence of infection, HIV negative test, and signed informed consent. All patients had to have been previously treated with at least one line of a cisplatin-containing regimen and were included if they were refractory after one or two line(s) of cisplatin-based CT, or had relapsed after two lines of a cisplatin-based CT.

Non-inclusion criteria are: patients with 'BEYER' score > 3, growing teratoma syndrome, possibility of being treated with a conventional cisplatin-based CT, and previous HD-CT regimen.

During the initial evaluation: each patient must have a clinical evaluation that includes measurements of tumor marker levels, and an imaging work up. The tumor marker levels are determined every week during all the sequence of treatment (normal level < 10 ng/ml for alpha-foetoprotein and < 2 mU/mL for HCG). The tumor mass is measured after the first two cycles of induction/mobilization therapy and at the end of the treatment.

Chemotherapy, patients are scheduled to receive 2 courses of front-line mobilization CT followed by 3 HD-CT supported by PBSCT. The front-line treatment consists in a combination of epirubicin, (100 mg/m² in a 30-minute infusion), and paclitaxel (Taxol, 250 mg/m² given in a 3-hour infusion), administered both on days 1 and 14. These 2 cycles are supported by filgrastim (Neupogen), 5 µg/kg, twice a day from days 2 and 15, respectively, until apheresis performed on days 10-13 and 24-27. Apheresis is stopped when at least 9 x 106 CD34+ cells/Kg of BW are obtained for the 3 grafts. A third cycle is permitted if the number of CD34+ cells is not achieved after the first 2 cycles, provided the patient was responsive to CT, or for any reason decided upon by the investigator.

The first HD-CT regimen consists in an association of thiotepa, 720 mg/m² and taxol, 360 mg/m², both administered in a continuous infusion over 3 days (D34 to D36). The first pack of CD34+ cells is infused on day 39. The second and the third courses (ICE) scheduled on days 62-66 and 90-94 respectively, consist in a combination of etoposide (150 mg/m² twice a day, in a 2-hour infusion, for 5 days), ifosfamide (2 400 mg/m²/d in a 3-hour infusion, for 5 days) supported by sodium mercaptoethanesulfonate (mesna, in a 30-minute infusion every 3 hours, during a 12-hour period, initiated at the same time as the ifosfamide infusion), and carboplatin (AUC 4/d, in a 6-hour infusion, for 5 days). Infusion of PBSCs is planned on days 71 and 99. During the 3 high-dose therapies, G-CSF is administered at a daily dose of 5µg/kg, from the day of PBSC infusion until PMN recovery (i.e., PMN > 1.5 x 109/L). Each of these ICE regimens is delayed if the PMN level is less than 1.5 x 109/L and/or the platelet level less than 100 x 109/L.

Toxicity and response to therapy are evaluated according to the ECOG and WHO criteria. The duration of response is calculated from the date of documented response to the date of progression. The duration of PFS and OS are calculated from the date of inclusion to the date of progression, or death if no progression (PFS), and the date of death (OS), according to Kaplan-Meier's method. Survival curves are established according to the classification proposed by BEYER et al. Progression, death from treatment and withdrawal from protocol for whatever reason are considered as treatment failures. Whenever possible, patients in clinical partial response (PR) with normal tumor markers (PRm-) will be proposed for surgery of residual masses at the end of the whole procedure. Sequential procedures are proposed in the case of multiple metastatic sites. If surgery is complete and the pathological examination does not show any viable tumor, patients will be considered as complete responders. If surgery is complete and the pathological examination showed persistent viable tumor, they will be considered as surgical complete response.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

Eligibility requirements includes the following criteria:

- Age >18 years and < 65

- Performance status < 3

- Histologically or biologically documented GCTs

- Testicular, abdominal, or mediastinal tumors

- Measurable or evaluable disease

- Life expectancy > 3 months

- Normal cardiac, liver, and renal function tests

- Absence of infection

- HIV negative test

- Signed informed consent

- All patients had to have been previously treated with at least one line of a cisplatin-containing regimen and were included if they were refractory after one or two line(s) of cisplatin-based CT, or had relapsed after two lines of a cisplatin-based CT

Exclusion Criteria:

- Fireproof diseases (progress unless month with regard to the last cycle of chemotherapy or in the course of chemotherapy)

- Relapses after complete answer obtained by surgery ( sCR )

- Neuropathy of superior rank or = II - renal Function (Office) superior creatinine or = 125 mmol/l and/or clearance of the creatinine subordinate or = II 60ml / mn

- Antecedents of congestive even compensated cardiac insufficiency

- Hurts of growing teratoma that is measurable hurts increasing by size (cutting) in the absence of rise of marker pens

- Extensive chemotherapy with support of haematopoietic stem cells. NB: A previous preventive irradiation under diaphragmatitis for a seminoma stage I (dose from 24 to 30 Gy in classic spreading) does not establish one against formal indication. However, an estimation clarifies capacities of the haematopoietic marrow is recommended with observation of the evolution of the NFP in the course of chemotherapy and quantification of cells CD 34 + in the peripheral blood. It's the same of the case where a chemotherapy by carboplatine was realized

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
epirubicin
epirubicin
Procedure:
high-dose and autologous stem cell transplantation
high-dose and autologous stem cell transplantation
Drug:
paclitaxel
paclitaxel
etoposide
etoposide
ifosfamide
ifosfamide
carboplatin
carboplatin

Locations

Country Name City State
France Hôpital TENON, Service d'Oncologie Médicale Paris

Sponsors (4)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Amgen, Baxter Healthcare Corporation, Ministry of Health, France

Country where clinical trial is conducted

France, 

References & Publications (1)

Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K, Gravis G, Delva R, Peny J, Viens P, Duclos B, De Revel T, Curé H, Gligorov J, Guillemaut S, Ségura C, Provent S, Droz JP, Culine S, Biron P; Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG). Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol. 2005 Mar;16(3):411-8. Epub 2005 Jan 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Complete response rate Complete response rate during de study Yes
Secondary Survival (overall and progression-free), toxicity, toxic-death rate. Survival (overall and progression-free), toxicity, toxic-death rate. during the study Yes
See also
  Status Clinical Trial Phase
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Terminated NCT02577172 - Testicular Cancer and Aerobic and Strength Training N/A
Completed NCT03403777 - Avelumab in Refractory Testicular Germ Cell Cancer. Phase 2
Completed NCT02890030 - The Platinum Study Comparison Group
Recruiting NCT05264337 - Lymphedema After Urologic Surgery
Active, not recruiting NCT03426865 - Role of Axumin PET Scan in Germ Cell Tumor
Completed NCT00001270 - Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma Phase 1
Completed NCT02459132 - High-Intensity Aerobic Interval Training in Testicular Cancer Survivors N/A
Completed NCT06309732 - GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) Phase 2
Terminated NCT02499952 - Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Phase 2
Recruiting NCT02304575 - Quality of Life Among Testicular Cancer Survivors N/A
Withdrawn NCT02492360 - Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy N/A
Completed NCT04122430 - Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours
Recruiting NCT02229916 - Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
Completed NCT02161692 - Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Phase 2
Completed NCT02966509 - Engagement of Patients With Advanced Cancer N/A
Recruiting NCT02341989 - Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer Phase 3
Completed NCT05056688 - Effect of Online Education Given to Young Adults on Testicular Cancer Health Beliefs and Behaviors N/A
Terminated NCT05229900 - A Study of SGN-ALPV in Advanced Solid Tumors Phase 1
Completed NCT00123773 - Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence Phase 2